The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma.
 
Saba Shaikh
No Relationships to Disclose
 
Xi Yang
No Relationships to Disclose
 
Dylan Fortman
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Diwakar Davar
Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences
Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences
Research Funding - Bristol-Myers Squibb; CellSight Technologies; Checkmate Pharmaceuticals; medpacto; Merck; Tesaro; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alphamab; Array BioPharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Compugen; CStone Pharmaceuticals; Eisai; EMD Serono; Incyte; Janssen; Merck; Mersana; Nektar; Novartis; Partner Therapeutics; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; Spring Bank; Synlogic; Tempest Therapeutics; Tesaro; TTC Oncology; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios; Array BioPharma; Astellas Pharma; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Corvus Pharmaceuticals (Inst); EMD Serono; Immatics; Incyte (Inst); Kadmon; Macrogenics (Inst); Merck (Inst); Moderna Therapeutics; Nektar; Spring bank; Trishula Therapeutics; Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Hassane M. Zarour
Consulting or Advisory Role - Bristol-Myers Squibb; Checkmate Pharmaceuticals; GlaxoSmithKline; Vedanta Biosciences
Research Funding - Checkmate Pharmaceuticals (Inst); Tesaro (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Elsevier; Harbour BioMed; Iovance Biotherapeutics; Istari Oncology; Novartis; OncoSec; Pfizer; Scopus BioPharma
Speakers' Bureau - BMS
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Yana G. Najjar
Consulting or Advisory Role - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer/EMD Serono (Inst)